




PHARMACEUTICAL 2017

LIXTE BIOTECHNOLOGY HOLDINGS
INC.
Rank 281 of 292





PHARMACEUTICAL 2017

LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 281 of 292

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 44% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 449% points.

The company's Economic Capital Ratio, given in the ranking table, is -541%, being 544% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	433
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	219
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0.18
Other Revenues	0
Property and Equipment	0
Research and Development	1,301
Selling, General and Administrative Expense	834

Output Variable	Value in 1000 USD
Assets	433
Liabilities	219
Expenses	2,135
Revenues	0
Stockholders Equity	215
Net Income	-2,135
Comprehensive Net Income	-2,135
Economic Capital Ratio	-541%